Engipharm
Engipharm, officially known as Engipharm S.L., is a prominent player in the pharmaceutical industry, headquartered in Spain (ES). Founded in 2005, the company has established itself as a leader in the development and manufacturing of high-quality pharmaceutical products, particularly in the areas of generic medicines and innovative drug delivery systems. With a strong operational presence across Europe and Latin America, Engipharm is recognised for its commitment to quality and compliance with international standards. The company’s core offerings include a diverse range of generic pharmaceuticals and specialised formulations, distinguished by their efficacy and safety profiles. Engipharm's dedication to research and development has led to significant milestones, positioning it as a trusted partner in the healthcare sector. Its reputation for excellence is further underscored by numerous industry accolades, reflecting its impact on improving patient outcomes globally.
DitchCarbon Score
How does Engipharm's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Engipharm's score of 14 is lower than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Engipharm's reported carbon emissions
Engipharm, headquartered in Spain (ES), currently does not have available carbon emissions data for recent years, as no specific figures have been provided. Consequently, there are no reported emissions in terms of Scope 1, 2, or 3. Additionally, the company has not outlined any formal reduction targets or commitments to the Science Based Targets initiative (SBTi) or other climate pledges. In the absence of specific emissions data or reduction initiatives, it is essential to note that many companies in the pharmaceutical industry are increasingly focusing on sustainability and carbon neutrality. Engipharm may be expected to align with industry standards and practices in addressing climate change, although specific commitments or targets have not been disclosed at this time.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Engipharm is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
